Brett Hart - Abbvie Independent Director


USD 143.06  0.05  0.035%   

Mr. Brett J. Hart is an Independent Director of the company. Mr. Hart is the executive vice president, chief administrative officer and general counsel of United Continental Holdings, Inc. and United Airlines, Inc., a position he has held since May 2017. He served as executive vice president and general counsel between February 2012 and May 2017. Mr. Hart also served as acting chief executive officer of UAL and United Airlines, Inc. from October 2015 to March 2016. From December 2010 to February 2012, he served as senior vice president, general counsel and secretary of UAL, United and Continental. From June 2009 to December 2010, Mr. Hart served as executive vice president, general counsel and corporate secretary at Sara Lee Corporationrationration.
Age: 51  Director Since 2016      
847 932 7900

Abbvie Management Efficiency

Abbvie Inc has return on total asset (ROA) of 8.14 % which means that it generated profit of $8.14 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 92.71 %, meaning that it created $92.71 on every $100 dollars invested by stockholders. Abbvie management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 73.65 B in liabilities with Debt to Equity (D/E) ratio of 4.51, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abbvie Inc has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Abbvie until it has trouble settling it off, either with new capital or with free cash flow. So, Abbvie's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbvie Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbvie to invest in growth at high rates of return. When we think about Abbvie's use of debt, we should always consider it together with cash and equity.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 50000 people. Abbvie Inc (ABBV) is traded on New York Stock Exchange in USA and employs 50,000 people.

Abbvie Inc Leadership Team

Elected by the shareholders, the Abbvie's board of directors comprises two types of representatives: Abbvie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbvie. The board's role is to monitor Abbvie's management team and ensure that shareholders' interests are well served. Abbvie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbvie's outside directors are responsible for providing unbiased perspectives on the board's policies.
Azita Gerhardt, Executive Vice President - Operations
Carlos Alban, Vice Chairman, Chief Commercial Officer
Robert Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer
Jeffrey Stewart, Executive Vice President, Chief Commercial Officer
Carrie Strom, Senior Vice President AbbVie and President Global Allergan Aesthetics
Brett Hart, Independent Director
William Chase, Executive Vice President - Finance and Administration
Roxanne Austin, Independent Director
Azita SalekiGerhardt, Executive Vice President - Operations
Thomas Freyman, Independent Director
Edward Rapp, Independent Director
Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee
Brian Durkin, Vice President Controller
Thomas Hurwich, Vice President Controller
Frederick Waddell, Independent Director
Robert Alpern, Independent Director
Thomas Hudson, Senior Vice President Research & Development and Chief Scientific Officer
Glenn Tilton, Lead Independent Director
Henry Gosebruch, Executive Vice President Chief Strategy Officer
Rebecca Roberts, Independent Director
Edward Liddy, Independent Director
William Burnside, Independent Director
Elaine Sorg, Senior Vice President U.S. Commercial Operations
Timothy Richmond, Chief Human Resource Officer, Executive Vice President
Nicholas Donoghoe, Senior Vice President - Enterprise Innovation
Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary
Roy Roberts, Independent Director
Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer
Melody Meyer, Independent Director

Abbvie Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbvie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Abbvie without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Correlation Analysis Now


Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Module

Pair Trading with Abbvie

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbvie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbvie will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abbvie

+0.86JNJJohnson Johnson TrendingPairCorr
+0.8MRKMerck Company TrendingPairCorr

Moving against Abbvie

-0.78DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr
-0.7WMTWalmart TrendingPairCorr
The ability to find closely correlated positions to Abbvie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbvie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbvie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbvie Inc to buy it.
The correlation of Abbvie is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbvie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbvie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbvie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the Abbvie Inc information on this page should be used as a complementary analysis to other Abbvie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Abbvie Stock analysis

When running Abbvie Inc price analysis, check to measure Abbvie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbvie is operating at the current time. Most of Abbvie's value examination focuses on studying past and present price action to predict the probability of Abbvie's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abbvie's price. Additionally, you may evaluate how the addition of Abbvie to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Transaction History
View history of all your transactions and understand their impact on performance
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
CEO Directory
Screen CEOs from public companies around the world
Is Abbvie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbvie. If investors know Abbvie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbvie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abbvie Inc is measured differently than its book value, which is the value of Abbvie that is recorded on the company's balance sheet. Investors also form their own opinion of Abbvie's value that differs from its market value or its book value, called intrinsic value, which is Abbvie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbvie's market value can be influenced by many factors that don't directly affect Abbvie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbvie's value and its price as these two are different measures arrived at by different means. Investors typically determine Abbvie value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbvie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.